Literature DB >> 35902729

Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma.

Jin Liu1,2,3, Binwen Sun1,2, Kun Guo1,4, Zhou Yang1, Yidan Zhao1, Mingwei Gao2, Zeli Yin1,2, Keqiu Jiang1, Chengyong Dong2, Zhenming Gao2, Mingliang Ye3, Jing Liu5, Liming Wang6,7.   

Abstract

Monocytes/macrophages, a plastic and heterogeneous cell population of the tumor microenvironment (TME), can constitute a major component of most solid tumors. Under the pressure of rapid proliferation of the tumor, monocytes/macrophages can be educated and foster immune tolerance via metabolic reprogramming. Our studies have shown that the activation of FABP5, a lipid-binding protein, decreases the rate of β-oxidation causing the accumulation of lipid droplets in monocytes. We found that hepatocellular carcinoma cells (HCC) increased IL-10 secretion by monocytes, which depended on the expression of FABP5 and suppressing of the PPARα pathway. Moreover, the elevated level of IL-10 promotes PD-L1 expression on Treg cells via the JNK-STAT3 pathway activation. We also observed that elevation of FABP5 in monocytes was negatively related to HCC patients' overall survival time. Thus, FABP5 promotes monocyte/macrophage lipid accumulation, fosters immune tolerance formation, and might represent itself as a therapeutic target in both tumor-associated monocytes (TAMs) and cancer cells.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 35902729     DOI: 10.1038/s41417-022-00510-0

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  45 in total

Review 1.  Macrophages and Metabolism in the Tumor Microenvironment.

Authors:  Ilio Vitale; Gwenola Manic; Lisa M Coussens; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Metab       Date:  2019-07-02       Impact factor: 27.287

Review 2.  Metabolic Reprogramming of Immune Cells in Cancer Progression.

Authors:  Subhra K Biswas
Journal:  Immunity       Date:  2015-09-15       Impact factor: 31.745

3.  Membrane Cholesterol Regulates Macrophage Plasticity in Cancer.

Authors:  Antonio Sica; Augusto Bleve; Marina Chiara Garassino
Journal:  Cell Metab       Date:  2019-06-04       Impact factor: 27.287

4.  Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis.

Authors:  Mathias Wenes; Min Shang; Mario Di Matteo; Jermaine Goveia; Rosa Martín-Pérez; Jens Serneels; Hans Prenen; Bart Ghesquière; Peter Carmeliet; Massimiliano Mazzone
Journal:  Cell Metab       Date:  2016-10-20       Impact factor: 27.287

5.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

Authors:  Jennifer E Lambert; Maria A Ramos-Roman; Jeffrey D Browning; Elizabeth J Parks
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

6.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

7.  Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.

Authors:  Dong-Ping Chen; Wan-Ru Ning; Ze-Zhou Jiang; Zhi-Peng Peng; Ling-Yan Zhu; Shi-Mei Zhuang; Dong-Ming Kuang; Limin Zheng; Yan Wu
Journal:  J Hepatol       Date:  2019-05-07       Impact factor: 25.083

8.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

9.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 10.  Competition for nutrients and its role in controlling immune responses.

Authors:  Nidhi Kedia-Mehta; David K Finlay
Journal:  Nat Commun       Date:  2019-05-09       Impact factor: 14.919

View more
  1 in total

1.  Central role of PD-L1 in cardioprotection resulting from P2Y4 nucleotide receptor loss.

Authors:  Michael Horckmans; Esteban Diaz Villamil; Lucas De Roeck; Didier Communi
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.